相关实验视频

Updated: Jul 5, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在急性白血病中检测与药物敏感性和耐药性相关的基因组结构变异

Darren Finlay¹, Rabi Murad¹, Karl Hong²

¹NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

|January 23, 2024

概括

光学基因组映射检测了急性白血病的新型结构变异,将特定的遗传变化与药物敏感性联系起来. 这促进了个性化治疗策略的推进,以获得更好的患者结果.

科学领域:

血液学血液学血液学
基因组学就是基因组学.
在瘤学瘤学.

背景情况:

在没有移植的情况下,急性白血病的存活率很低,化学疗法的副作用很大.
了解白血病的演变对于确定新的治疗点和药物疗法至关重要.
基因组重组和结构变异 (SVs) 与癌症发病,进展和耐药性有关.

研究的目的:

利用光学基因组映射 (OGM) 在白血病患者样本中检测已知和新型SV.
将SV数据与药物化学敏感性概况集成,以提供个性化的治疗指导.
将特定的基因组变化与患者对FDA批准的瘤药物的反应联系起来.

主要方法:

光学基因组映射 (OGM) 用于高分辨率检测和定量结构变异 (SVs).
化学敏感性测定使用FDA批准的瘤药物在患者衍生样本上进行.
综合性分析将检测到的基因组重组与药物敏感性概况相关联.

主要成果:

在高颗粒度的白血病患者中,OGM成功识别了已知和新型的SV.
插入MUSK基因与对Idarubicin的敏感性增加有关.
在KMT2A基因中的部分并列重复与Cytarabine的疗效相关.

结论:

转基因生物提供了一种公正的方法来检测急性白血病中临床相关的SVs.
对基因组数据和药物敏感性的综合分析可以指导个性化治疗选择.
识别特定的SV可以预测患者对前线白血病治疗的反应,提高治疗疗效.

关键词:

化学脆弱性化学脆弱性药物查对药物进行查.这种白血病是白血病.通过光学基因组映射进行基因组映射.结构变体结构变体

更多相关视频

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...